Oral pentoxifylline in therapy-resistant idiopathic OAT syndrome.
After previous treatment failure using tamoxifen either alone or in combination with kallikrein, 25 patients with idiopathic oligoasthenoteratozoospermia (OAT syndrome) were subjected to 3 months of treatment with pentoxifylline at a dosage of 1200 mg/day. The only statistically significant (p < .008) improvement detected in the post-therapeutic spermiograms was an increase of normal forms. All other ejaculate parameters (density, motility, swelling test, penetration test) remained unchanged, and there was only one post-therapeutic pregnancy. It would appear the pentoxifylline after failure of established treatment modalities is not a therapy of choice in idiopathic OAT syndrome.
Maier
U
U
Department of Urology, University of Vienna Medical School, Austria.
Szabo
N
N
Ludvik
G
G
D000284:Administration, Oral; D000328:Adult; D006801:Humans; D007610:Kallikreins / Q000627:therapeutic use; D008297:Male; D009845:Oligospermia / Q000188:drug therapy*; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D013081:Sperm Motility; D013094:Spermatozoa / Q000002:abnormalities / Q000502:physiology; D013577:Syndrome; D013629:Tamoxifen / Q000627:therapeutic use; D017211:Treatment Failure
D013629:Tamoxifen; D007610:Kallikreins; D010431:Pentoxifylline